Advertisement

News Stories

May, 2019

An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.

The presentation on Saturday, May 18, 4:40-4:50 p.m. included the total events analysis from the REDUCE-IT study, as first presented March 2019 and published in the Journal of the American College of Cardiology.

0
No votes yet
Name: Top Stories
May, 2019

Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session.

Inclisiran, the first cholesterol-lowering therapy in the siRNA class, has the potential to deliver consistent lowering of LDL cholesterol through twice-a-year dosing.

Among the results presented today:

0
No votes yet
Name: Top Stories
May, 2019

MIAMI, Fla. – (May 18, 2019) -- Clinical lipidology’s best and brightest up-and-comers have been singled out for their exceptional abstracts at the National Lipid Association’s (NLA) 2019 Scientific Sessions, taking place May 16 – 19 in Miami.

Five Young Investigator Abstract Award Winners were selected from those engaged in innovative research work in the field of clinical lipidology and cardiovascular disease prevention. The competition is open to in-training students, residents, fellows and NLA members in practice for five years or less.

0
No votes yet
Name: NLA News

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service